High acceptance and reported efficacy of cannabis for pain management in patients with rheumatic diseases in Germany: a postlegalisation survey

Abstract Objectives: Cannabis legalisation in North America has led to increased use of medical cannabis (MC) among patients with inflammatory rheumatic diseases (IRDs). In Europe, there are still no epidemiologic data on the patterns of cannabis consumption in this population. Thus, this study aimed to assess the prevalence of cannabis consumption among patients with IRD in Germany just after legalisation and to analyse its associations with demographic and clinical factors, acceptance, and physician experience with prescription. Methods: Two surveys were